Nephrology Department, The First People's Hospital of Foshan, Foshan 528000, China.
Department of Medicine & Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Int J Mol Sci. 2022 Apr 28;23(9):4908. doi: 10.3390/ijms23094908.
Renal inflammation is an initial pathological process during progressive renal injury regardless of the initial cause. Macrophage migration inhibitory factor (MIF) is a truly proinflammatory stress mediator that is highly expressed in a variety of both inflammatory cells and intrinsic kidney cells. MIF is released from the diseased kidney immediately upon stimulation to trigger renal inflammation by activating macrophages and T cells, and promoting the production of proinflammatory cytokines, chemokines, and stress molecules via signaling pathways involving the CD74/CD44 and chemokine receptors CXCR2, CXCR4, and CXCR7 signaling. In addition, MIF can function as a stress molecule to counter-regulate the immunosuppressive effect of glucocorticoid in renal inflammation. Given the critical position of MIF in the upstream inflammatory cascade, this review focuses on the regulatory role and molecular mechanisms of MIF in kidney diseases. The therapeutic potential of targeting MIF signaling to treat kidney diseases is also discussed.
肾炎症是渐进性肾损伤过程中的初始病理过程,无论初始原因如何。巨噬细胞移动抑制因子(MIF)是一种真正的促炎应激介质,在多种炎症细胞和固有肾细胞中高度表达。MIF 会在受到刺激时从患病肾脏中释放出来,通过激活巨噬细胞和 T 细胞,以及通过涉及 CD74/CD44 和趋化因子受体 CXCR2、CXCR4 和 CXCR7 信号的信号通路,促进促炎细胞因子、趋化因子和应激分子的产生,从而引发肾炎症。此外,MIF 可以作为一种应激分子,在肾炎症中抵消糖皮质激素的免疫抑制作用。鉴于 MIF 在炎症级联反应上游的关键位置,本综述重点讨论了 MIF 在肾脏疾病中的调节作用和分子机制。还讨论了针对 MIF 信号转导治疗肾脏疾病的治疗潜力。